List of Juluca drug patents

Juluca is owned by Viiv Hlthcare.

Juluca contains Dolutegravir Sodium; Rilpivirine Hydrochloride.

Juluca has a total of 6 drug patents out of which 1 drug patent has expired.

Expired drug patents of Juluca are:

  • US8101629

Juluca was authorised for market use on 21 November, 2017.

Juluca is available in tablet;oral dosage forms.

Juluca can be used as treatment of hiv infection.

The generics of Juluca are possible to be released after 24 January, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2023

(2 months from now)

US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(2 years from now)

US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(6 years from now)

US10426780 VIIV HLTHCARE Antiviral therapy
Jan, 2031

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101629 VIIV HLTHCARE Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
Aug, 2022

(5 months ago)


Market Authorisation Date: 21 November, 2017

Treatment: Treatment of hiv infection


How can I launch a generic of JULUCA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in